128 related articles for article (PubMed ID: 25804228)
1. The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats.
Tkalia IG; Vorobyova LI; Grabovoy AN; Svintsitsky VS; Tarasova TO
Exp Oncol; 2015 Mar; 37(1):30-5. PubMed ID: 25804228
[TBL] [Abstract][Full Text] [Related]
2. Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor.
Tkalia IG; Vorobyova LI; Grabovoy AN; Svintsitsky VS; Tarasova TO; Lukyanova NY; Todor IN; Chekhun VF
Exp Oncol; 2014 Sep; 36(3):184-90. PubMed ID: 25265352
[TBL] [Abstract][Full Text] [Related]
3. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: a pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin.
Falkson CI; Falkson HC; Falkson G
Oncology; 1996; 53(4):313-7. PubMed ID: 8692536
[TBL] [Abstract][Full Text] [Related]
5. Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone.
Jannuzzo MG; Di Salle E; Spinelli R; Pirotta N; Buchan P; Bello A
Breast Cancer Res Treat; 2009 Feb; 113(3):491-9. PubMed ID: 18330698
[TBL] [Abstract][Full Text] [Related]
6. Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.
Frampton JE
Drugs; 2017 Dec; 77(18):2037-2048. PubMed ID: 29177573
[TBL] [Abstract][Full Text] [Related]
7. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.
Zhao H; Li X; Chen D; Cai J; Fu Y; Kang H; Gao J; Gao K; Du N
Med Oncol; 2015 Feb; 32(2):292. PubMed ID: 25609006
[TBL] [Abstract][Full Text] [Related]
9. Exemestane with ovarian suppression in premenopausal breast cancer.
Prasad V
N Engl J Med; 2014 Oct; 371(14):1358. PubMed ID: 25271613
[No Abstract] [Full Text] [Related]
10. Exemestane with ovarian suppression in premenopausal breast cancer.
Chlebowski RT; Pan K
N Engl J Med; 2014 Oct; 371(14):1358. PubMed ID: 25271612
[No Abstract] [Full Text] [Related]
11. Exemestane with ovarian suppression in premenopausal breast cancer.
Amoroso V; Berruti A; Simoncini E
N Engl J Med; 2014 Oct; 371(14):1357. PubMed ID: 25271611
[No Abstract] [Full Text] [Related]
12. Exemestane with ovarian suppression in premenopausal breast cancer.
Pagani O; Regan MM; Francis PA; ;
N Engl J Med; 2014 Oct; 371(14):1358-9. PubMed ID: 25271610
[No Abstract] [Full Text] [Related]
13. Comparative efficacy evaluation of catheter intraperitoneal chemotherapy, normothermic and hyperthermic chemoperfusion in a rat model of ascitic ovarian cancer.
Bespalov VG; Alvovsky IK; Tochilnikov GV; Stukov AN; Vyshinskaya EA; Semenov AL; Vasilyeva IN; Belyaeva OA; Kireeva GS; Senchik KY; Zhilinskaya NT; Von JD; Krasilnikova LA; Alexandrov VA; Khromov-Borisov NN; Baranenko DA; Belyaev AM
Int J Hyperthermia; 2018 Aug; 34(5):545-550. PubMed ID: 28893108
[TBL] [Abstract][Full Text] [Related]
14. Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice.
Lin QY; Wang YF; Weng HN; Sheng XJ; Jiang QP; Yang ZY
J Zhejiang Univ Sci B; 2012 Nov; 13(11):894-903. PubMed ID: 23125082
[TBL] [Abstract][Full Text] [Related]
15. Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).
Kwok CW; Treeck O; Buchholz S; Seitz S; Ortmann O; Engel JB
Target Oncol; 2015 Sep; 10(3):365-73. PubMed ID: 25293576
[TBL] [Abstract][Full Text] [Related]
16. [Antitumor activity of dioxadet compared with cisplatin on ascitic ovarian tumor in rats].
Bespalov VG; Beliaeva OA; Panchenko AV; Stukov AN; Gershanovich ML; Murazov IaG; Kon'kov SA; Kil'maeva NE; Krylova IM; Mironiuk TA; Latipova DKh
Vopr Onkol; 2011; 57(6):771-4. PubMed ID: 22416396
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
[TBL] [Abstract][Full Text] [Related]
18. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
19. [Avastin combined with cisplan inhibits malignant ascites production in nude mice bearing transplanted ovary carcinoma with high VEGF expression].
Cai YJ; Zheng DY; Luo RC; Chen JZ; Li AM; Xi JL; Ding XM
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):647-9. PubMed ID: 17545079
[TBL] [Abstract][Full Text] [Related]
20. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
